Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is a leading clinical-stage biotechnology company dedicated to developing innovative medicines that address intractable diseases through gene silencing. The company utilizes an extensive array of RNA chemistries and efficient delivery systems to harness the power of RNA interference (RNAi) mechanisms. This approach allows for the rapid, deep, and durable knockdown of target genes, thereby reducing the production of specific proteins that cause diseases.
Arrowhead's groundbreaking therapies are at the forefront of genetic-based treatments, presenting potential life-changing solutions for patients. Notable among their technologies is the Targeted RNAi Molecule (TRiMTM) platform. This platform employs ligand-mediated delivery for tissue-specific targeting while maintaining structural simplicity. The TRiMTM platform is built upon over a decade of research in actively targeted drug delivery, offering advantages such as simplified manufacturing processes and enhanced specificity.
The company's diverse portfolio includes promising treatments for conditions such as Hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular diseases. Arrowhead is continuously engaged in advancing its clinical programs and forging strategic partnerships to bring its novel therapies to market.
With headquarters in Pasadena, California, Arrowhead Pharmaceuticals remains committed to transforming the landscape of genetic medicine and improving patient outcomes worldwide. Their dedication to scientific innovation and patient care positions them as a pivotal player in the biotechnology sector.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is scheduled to participate in several key events from November 12-30, 2021. Highlights include presentations during the Liver Meeting (AASLD) featuring findings on ARO-AAT and ARO-HSD therapies, as well as results from the Phase 2B REEF-1 Study for chronic hepatitis B. Additionally, CEO Chris Anzalone will engage in fireside chats at both the Jefferies London Healthcare Conference and the Piper Sandler Healthcare Conference. These events underline Arrowhead’s commitment to advancing RNA interference therapeutics.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has submitted an application for clearance to initiate a Phase 1/2a clinical trial of ARO-C3, an investigational RNA interference therapeutic for complement-mediated diseases. The trial aims to evaluate safety and pharmacokinetics in healthy volunteers and patients with specific renal conditions. Arrowhead will host a KOL webinar on October 26, 2021, to elaborate on ARO-C3's development and its potential to treat unmet medical needs in renal and hematology diseases, including IgA nephropathy and paroxysmal nocturnal hemoglobinuria.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a KOL webinar on October 26, 2021, at 3:00 p.m. ET to discuss ARO-C3, an investigational RNAi therapeutic for complement mediated diseases. Presenters include experts Richard J. Glassock and Peter Browett, who will cover treatment landscapes and unmet needs in renal and hematological complement mediated diseases. The management team will explain preclinical data and clinical plans, aiming to file a CTA in Q4 2021 for clinical studies. Access the webinar on Arrowhead's website under Events and Presentations.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated dosing for the first patient in the AROAPOC3-2002 Phase 2b study of ARO-APOC3, targeting adults with mixed dyslipidemia. This investigational RNAi therapeutic aims to address severe hypertriglyceridemia, mixed dyslipidemia, and familial chylomicronemia syndrome. As part of its clinical program, Arrowhead plans to start a Phase 3 study for patients with familial chylomicronemia syndrome in Q4 2021. Approximately 320 participants will be enrolled in the ongoing study.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in key upcoming events in October 2021. On October 4, Vince Anzalone will join a fireside chat at Chardan's 5th Annual Genetics Medicines Conference. Following that, on October 12, James Hamilton will present at the H.C. Wainwright 5th Annual NASH Investor Conference. For detailed presentation materials and live webcast links, visit the Events and Presentations section on Arrowhead's website.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a milestone payment of
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in several upcoming virtual investing events. Key dates include the Citi’s 16th Annual BioPharma Virtual Conference from September 8-10, with Arrowhead hosting virtual investor meetings on September 9. CEO Chris Anzalone will present during the HC Wainwright 23rd Annual Global Investment Conference on September 13 and the Cantor Virtual Global Healthcare Conference on September 29. These events will showcase Arrowhead's innovative RNA interference therapeutics targeting intractable diseases.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported financial results for Q3 2021, with revenue rising to $45.9 million compared to $27.4 million in Q3 2020. Operating loss widened to $31.9 million, and net loss increased to $29.9 million, or $(0.29) per diluted share. Notable achievements include receiving Breakthrough Therapy designation for ARO-AAT and positive interim study results for ARO-HSD and ARO-HIF2. The company maintains cash resources of $644.7 million, supporting ongoing clinical trials.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that the U.S. FDA granted Breakthrough Therapy designation for its investigational RNA interference therapeutic, ARO-AAT, co-developed with Takeda, aimed at treating alpha-1 antitrypsin deficiency (AATD)-associated liver disease. ARO-AAT also has Orphan Drug and Fast Track designations. The Phase 2 SEQUOIA study has reached full enrollment of 40 patients, with interim results suggesting a significant reduction in toxic Z-AAT protein production, potentially improving liver disease outcomes.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ending June 30, 2021. Investors can access the live audio on the Company's website. A replay will be available shortly after the call concludes. Arrowhead focuses on developing therapies that utilize RNA interference to address intractable diseases by silencing specific genes.
FAQ
What is the current stock price of Arrowhead Pharma (ARWR)?
What is the market cap of Arrowhead Pharma (ARWR)?
What is the primary focus of Arrowhead Pharmaceuticals?
What is RNA interference (RNAi)?
What is the TRiMTM platform?
Which diseases does Arrowhead Pharmaceuticals address?
Where is Arrowhead Pharmaceuticals headquartered?
What are the latest developments at Arrowhead Pharmaceuticals?
How does Arrowhead's technology benefit patients?
What are some advantages of the TRiMTM platform?
Is Arrowhead publicly traded?
How can I invest in Arrowhead Pharmaceuticals?
